ATRACTIB

OFFICIAL TITLE: PHASE II CLINICAL TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER 

PROJECT DETAILS

THIS IS A MULTICENTRE, OPEN-LABEL, SINGLE-ARM, PHASE II CLINICAL TRIAL. MEN AND WOMEN AGE ≥ 18 YEARS WITH PREVIOUSLY UNTREATED UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TRIPLE-NEGATIVE BREAST CANCER (TNBC) THAT IS NOT AMENABLE TO RESECTION WITH CURATIVE INTENT. PATIENTS IN THIS SINGLE-ARM STUDY (N=100) WILL RECEIVE TREATMENT (INTRAVENOUS INFUSION) WITH ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®).

THE MAIN OBJECTIVE IS TO EVALUATE THE EFFICACY –IN TERMS OF PROGRESSION-FREE SURVIVAL (PFS)– OF FIRST LINE ATEZOLIZUMAB IN COMBINATION WITH PACLITAXEL AND BEVACIZUMAB (AVASTIN®) IN PATIENTS WITH UNRESECTABLE LOCALLY ADVANCED OR METASTATIC TNBC.

​

ATRACTIB AT CLINICALTRIALS.GOV

TUMOR TYPE

PHASE

N

SITES

COUNTRY

STATUS

Start up

ATRACTIB SITES

BACK TO CURRENT PROJECTS